Combined targeted therapy and immunotherapy in the treatment of advanced melanoma

Recently, a CTLA-4 antibody and BRAF inhibitors showed survival benefits in advance melanoma treatment. The documentation of immune infiltrates in melanomas early during BRAF inhibitor therapy provides a scientific rationale for combination therapy with both treatments with possible synergistic bene...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilmott, James S., Scolyer, Richard A., Long, Georgina V., Hersey, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489773/
https://www.ncbi.nlm.nih.gov/pubmed/23189245
http://dx.doi.org/10.4161/onci.19865
_version_ 1782248779909431296
author Wilmott, James S.
Scolyer, Richard A.
Long, Georgina V.
Hersey, Peter
author_facet Wilmott, James S.
Scolyer, Richard A.
Long, Georgina V.
Hersey, Peter
author_sort Wilmott, James S.
collection PubMed
description Recently, a CTLA-4 antibody and BRAF inhibitors showed survival benefits in advance melanoma treatment. The documentation of immune infiltrates in melanomas early during BRAF inhibitor therapy provides a scientific rationale for combination therapy with both treatments with possible synergistic benefits. This commentary reviews immune responses induced by BRAF inhibitors.
format Online
Article
Text
id pubmed-3489773
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-34897732012-11-27 Combined targeted therapy and immunotherapy in the treatment of advanced melanoma Wilmott, James S. Scolyer, Richard A. Long, Georgina V. Hersey, Peter Oncoimmunology Author's View Recently, a CTLA-4 antibody and BRAF inhibitors showed survival benefits in advance melanoma treatment. The documentation of immune infiltrates in melanomas early during BRAF inhibitor therapy provides a scientific rationale for combination therapy with both treatments with possible synergistic benefits. This commentary reviews immune responses induced by BRAF inhibitors. Landes Bioscience 2012-09-01 /pmc/articles/PMC3489773/ /pubmed/23189245 http://dx.doi.org/10.4161/onci.19865 Text en Copyright © 2012 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Wilmott, James S.
Scolyer, Richard A.
Long, Georgina V.
Hersey, Peter
Combined targeted therapy and immunotherapy in the treatment of advanced melanoma
title Combined targeted therapy and immunotherapy in the treatment of advanced melanoma
title_full Combined targeted therapy and immunotherapy in the treatment of advanced melanoma
title_fullStr Combined targeted therapy and immunotherapy in the treatment of advanced melanoma
title_full_unstemmed Combined targeted therapy and immunotherapy in the treatment of advanced melanoma
title_short Combined targeted therapy and immunotherapy in the treatment of advanced melanoma
title_sort combined targeted therapy and immunotherapy in the treatment of advanced melanoma
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489773/
https://www.ncbi.nlm.nih.gov/pubmed/23189245
http://dx.doi.org/10.4161/onci.19865
work_keys_str_mv AT wilmottjamess combinedtargetedtherapyandimmunotherapyinthetreatmentofadvancedmelanoma
AT scolyerricharda combinedtargetedtherapyandimmunotherapyinthetreatmentofadvancedmelanoma
AT longgeorginav combinedtargetedtherapyandimmunotherapyinthetreatmentofadvancedmelanoma
AT herseypeter combinedtargetedtherapyandimmunotherapyinthetreatmentofadvancedmelanoma

Ejemplares similares